An Open-label, Parallel Group Study to Explore the Pharmacokinetics of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors and Normal or Reduced Hepatic Function According to the Child-Pugh System.
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2012
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 31 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Aug 2008 New trial record.